The Pharmaletter
Hikma Pharmaceuticals
Founding and History
Hikma was founded in 1978 and has grown into a global generics company listed in London (FTSE 100). In November 2025, the company confirmed full-year guidance while updating its medium-term growth outlook and disclosed a delay to the ramp-up of its new Bedford, Ohio injectable facility, now expected to be fully operational in late 2027. On 15 December 2025, Hikma announced a CEO change: Riad Mishlawi stepped down and Executive Chairman Said Darwazah assumed CEO responsibilities.
Therapy Areas and Focus
Hikma’s portfolio is organized around three operating segments:
- Injectables: generic injectable medicines supplied primarily to hospitals and health systems
- Generics: oral and other non-injectable generic medicines
- Branded: branded generics and specialty products, with a strong presence in the MENA region
Technology Platforms and Modalities
Hikma is a scale manufacturer and lifecycle manager of established medicines. Capabilities include sterile injectables manufacturing and complex generics, plus development, regulatory filing, and supply-chain execution across high-volume hospital channels. The company also pursues selected portfolio additions through acquisitions of approved dossiers (ANDAs) and in-licensing.
Key Personnel
Said Darwazah is Executive Chairman and, since 15 December 2025, has assumed CEO responsibilities. Hikma is led by a senior executive team spanning manufacturing, quality, commercial operations, R&D, and regional business units.
Strategic Partnerships
Hikma supplements internal development with commercial and development partnerships and selective acquisitions to expand its U.S. and international portfolios. Recent examples include product-facing collaborations for U.S. launches and the April 2025 acquisition of an FDA-approved ANDA for trametinib tablets from Novugen.
FAQ Section
Hikma manufactures and supplies generic and branded medicines at scale, with a core strength in sterile injectables for hospital markets. The business is built around development and regulatory execution, reliable manufacturing, and broad commercial access in the U.S., MENA, and Europe.
Hikma is not disease-area concentrated. Its products span multiple therapeutic categories typical of large generics and hospital suppliers, with the mix shaped by market demand, portfolio economics, and regulatory opportunity.
Hikma’s “pipeline” is a flow of product launches and portfolio additions rather than a clinical-stage R&D pipeline. The company regularly introduces new injectable and generic products (including complex injectables and biosimilar-referenced offerings) and adds approved dossiers through acquisition when strategically relevant.
Recent disclosed events include:
- 19 January 2026: Hikma announced the launch of denosumab-qbde products Enoby and Xtrenbo, referencing Prolia and Xgeva.
- 15 December 2025: Hikma announced a CEO change, with Said Darwazah assuming CEO responsibilities.
- 8 December 2025: Hikma announced the U.S. launch of TYZAVAN (vancomycin injection, USP).
- 6 November 2025: Hikma confirmed 2025 guidance and updated its medium-term outlook, including disclosure of delays at its Bedford, Ohio injectable facility.
- 17 April 2025: Hikma announced acquisition of an FDA-approved ANDA for trametinib tablets from Novugen.
Hikma does not typically generate pivotal clinical datasets as a core value driver, as its portfolio is primarily based on generics, complex generics, and referenced products supported by regulatory pathways such as ANDAs and related comparability requirements.
Key milestones are tied to filings, approvals, and launches across the Injectables and Generics businesses, and to operational delivery against capacity expansion plans. A specific operational milestone highlighted in November 2025 was the timeline to full operation for the Bedford, Ohio injectable facility, now guided to late 2027.
Hikma is led by an experienced executive chairman who has previously served as CEO and reassumed CEO responsibilities in December 2025. The leadership structure is typical of a global generics manufacturer, with senior ownership of quality and compliance, sterile manufacturing, supply chain, product development, and regional commercial execution.
Latest Hikma Pharmaceuticals News
Today's issue
| Headless Content Management with Blaze